Genoptix to participate in Aetna's national provider network to offer laboratory and diagnostic services

Genoptix, Inc. (Nasdaq: GXDX) today announced that it will participate in Aetna's (AET) national provider network to offer specialized laboratory and comprehensive diagnostic services designed to optimize the care of patients suffering from hematomalignancies, or cancers of the blood and bone marrow, including leukemia and lymphoma.

As a result, physicians will have additional choices for in-network specialty lab services for Aetna members. Aetna members could also benefit from lower out-of-pocket costs for Genoptix's laboratory services since copays, deductibles and coinsurance will be based on their in-network benefit levels and established rates for Genoptix's laboratory services.  The three-year agreement with Aetna, one of the nation's largest health benefits companies serving 19 million medical members, is effective April 1, 2010. Additional terms of the contract were not disclosed.

"We are excited to announce our contract with Aetna, a significant milestone for Genoptix," said Tina S. Nova, Ph.D., President and CEO of Genoptix.  "This relationship gives us the opportunity to make our specialized diagnostic services more accessible to Aetna's participating physicians and their patients across the country. We are proud to extend the benefits afforded by our offerings and our commitment to maintaining the highest standards in diagnostics for our physician customers."